MyFinsight
Home
Blog
About
Contact
Download
Download image
Maturities of short-term
investments
$140,290K
Proceeds from sale of
common stock in...
$14,904K
Proceeds from issuance of
common stock under...
$559K
Proceeds from issuance of
common stock upon...
$547K
Net cash provided by
(used in) investing...
$126,077K
Net cash provided by
financing activities
$10,857K
Canceled cashflow
$14,213K
Canceled cashflow
$5,153K
Net increase in cash
and cash...
$52,323K
Canceled cashflow
$84,611K
Purchases of short-term
investments
$14,086K
Purchase of property and
equipment
$127K
Share-based compensation
expense
$11,250K
Accrued and other
liabilities
$4,612K
Prepaid expenses and
other assets
-$3,370K
Accounts payable
$1,546K
Non-cash interest
expense
$308K
Depreciation and
amortization
$110K
something is missing
-$4,944K
Payments of issuance
costs associated with...
$209K
Net cash used in
operating activities
-$84,611K
Canceled cashflow
$21,196K
License
revenue-License
$70,000K
Other items
-$5,874K
Unbilled revenue
$70,000K
Net loss
-$34,599K
Canceled cashflow
$75,874K
Accretion and
amortization of...
$1,133K
Non-cash lease expense
-$13K
Segment research and
development expense
$81,105K
Segment general and
administrative expense
$18,118K
Share-based compensation
expense (see note 10)
$11,250K
Back
Back
Cash Flow
source: myfinsight.com
Viridian Therapeutics, Inc. DE (VRDN)
Viridian Therapeutics, Inc. DE (VRDN)